S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

NewAmsterdam Pharma (NAMS) News Today

$21.56
+0.44 (+2.08%)
(As of 02/21/2024 ET)
SourceHeadline
msn.com logoList of Universities that offer pharmacy in South Africa in 2024
msn.com - February 20 at 12:38 AM
finanznachrichten.de logoNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
finanznachrichten.de - February 16 at 2:36 AM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $20.00
marketbeat.com - February 14 at 12:01 PM
seekingalpha.com logoNewAmsterdam Pharma prices $175M share offering
seekingalpha.com - February 14 at 4:00 AM
finance.yahoo.com logoNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
finance.yahoo.com - February 14 at 3:13 AM
globenewswire.com logoNewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
globenewswire.com - February 13 at 10:40 PM
finance.yahoo.com logoNewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
finance.yahoo.com - February 13 at 5:11 PM
markets.businessinsider.com logoBuy Rating on NewAmsterdam Pharma: Underappreciated Potential of Obicetrapib in CVD Market
markets.businessinsider.com - February 13 at 12:10 PM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 8.6%
marketbeat.com - February 12 at 4:02 PM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $19.57
marketbeat.com - February 9 at 1:32 PM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 6.1%
marketbeat.com - February 2 at 2:18 PM
finance.yahoo.com logoNewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
finance.yahoo.com - February 1 at 7:13 PM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 16.0% in January
marketbeat.com - January 28 at 10:52 AM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Guggenheim
marketbeat.com - January 18 at 7:25 AM
msn.com logoCholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says
msn.com - January 16 at 7:37 PM
marketbeat.com logoNewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Piper Sandler
marketbeat.com - January 16 at 9:08 AM
finance.yahoo.com logoNewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
finance.yahoo.com - January 8 at 8:13 AM
finanznachrichten.de logoNewAmsterdam Pharma N.V.: NewAmsterdam Pharma Announces 2024 Strategic Priorities
finanznachrichten.de - January 4 at 3:34 PM
finance.yahoo.com logoInstitutions own 18% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares but private equity firms control 52% of the company
finance.yahoo.com - January 1 at 12:16 PM
marketbeat.com logoRA Capital Management L.P. Purchases 5,000,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)
marketbeat.com - December 12 at 9:51 AM
marketbeat.com logoBain Capital Life Sciences Investors LLC Purchases 2,173,913 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)
marketbeat.com - December 11 at 8:47 AM
markets.businessinsider.com logoRBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
markets.businessinsider.com - November 16 at 8:38 AM
finance.yahoo.com logoNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
finance.yahoo.com - November 13 at 10:36 AM
morningstar.com logoNewAmsterdam Pharma Co NV NAMS
morningstar.com - November 8 at 7:34 PM
finance.yahoo.com logoRBC initiates coverage of NewAmsterdam on CETP inhibitor
finance.yahoo.com - October 31 at 3:12 PM
msn.com logoRBC Capital Initiates Coverage of NewAmsterdam Pharma (NAMS) with Outperform Recommendation
msn.com - October 30 at 5:46 PM
cnbc.com logoThis biotech developing a cholesterol drug has a chance to triple, RBC predicts
cnbc.com - October 30 at 12:37 PM
marketwatch.com logoNewAmsterdam Pharma Names Ian Somaiya Chief Financial Officer
marketwatch.com - October 23 at 9:28 AM
finance.yahoo.com logoNewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
finance.yahoo.com - October 23 at 9:28 AM
msn.com logoNewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs
msn.com - October 2 at 10:58 PM
fool.com logoNewAmsterdam Pharma (NASDAQ: NAMS)
fool.com - September 22 at 6:50 PM
finance.yahoo.com logoNewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
finance.yahoo.com - September 21 at 10:10 AM
finance.yahoo.com logoNewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 8:16 AM
msn.com logoNewAmsterdam Pharma: Best Cardiovascular Biotech In 2023
msn.com - August 19 at 4:02 PM
markets.businessinsider.com logoAnalysts Are Bullish on These Healthcare Stocks: NewAmsterdam Pharma Company (NAMS), Legend Biotech (LEGN)
markets.businessinsider.com - August 16 at 10:01 AM
marketbeat.com logoGMT Capital Corp Buys 83,800 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)
marketbeat.com - August 11 at 6:25 PM
finance.yahoo.com logoNewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)
finance.yahoo.com - August 10 at 8:26 AM
finance.yahoo.com logoNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
finance.yahoo.com - August 7 at 7:43 AM
finance.yahoo.com logoRA Capital Management, L.P. Boosts Position in NewAmsterdam Pharma Co NV
finance.yahoo.com - August 2 at 2:30 PM
gurufocus.com logoRA Capital Management, L.P. Acquires Stake in NewAmsterdam Pharma Co NV
gurufocus.com - August 2 at 3:10 AM
finance.yahoo.com logoNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
finance.yahoo.com - July 25 at 6:25 PM
finance.yahoo.com logoInvesting in NewAmsterdam Pharma (NASDAQ:NAMS) a year ago would have delivered you a 21% gain
finance.yahoo.com - July 17 at 9:32 AM
seekingalpha.com logoNewAmsterdam Pharma: Exciting Cardiovascular Drug Targeting The Market
seekingalpha.com - July 4 at 10:14 PM
seekingalpha.com logoNewAmsterdam Pharma: Excellent LDL-C Data But Unknown In The U.S.
seekingalpha.com - June 19 at 8:22 AM
finance.yahoo.com logoNewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
finance.yahoo.com - June 9 at 4:31 PM
finance.yahoo.com logoAfter Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
finance.yahoo.com - June 8 at 2:33 PM
msn.com logoWhy Shares of NewAmsterdam Pharma Were Plummeting on Wednesday
msn.com - June 7 at 6:30 PM
marketwatch.com logoNewAmsterdam Pharma Shares Slide After Secondary Offering >NAMS
marketwatch.com - June 7 at 1:29 PM
msn.com logoNewAmsterdam Pharma shares dip on pricing upsized secondary stock offering at $11.50/share
msn.com - June 7 at 8:29 AM
finance.yahoo.com logoNewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
finance.yahoo.com - June 7 at 3:29 AM
Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.



NAMS Media Mentions By Week

NAMS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NAMS
News Sentiment

0.32

0.50

Average
Medical
News Sentiment

NAMS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NAMS Articles
This Week

3

1

NAMS Articles
Average Week

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NAMS) was last updated on 2/22/2024 by MarketBeat.com Staff